Question explored with the scientific record
Women over 50 taking oestrogen due to hysterectomy. How long should it be taken for, what are the repercussions for taking too much, what happens when we stop taking it.
The short version: there is no clean answer for how long to take estrogen after hysterectomy, because the evidence retrieved here is thin, mixed, and mostly about other questions.
The evidence you got does not directly answer your three questions. It is a grab bag of studies on estrogen in different contexts, from thyroid effects to prostate cancer to bone density. That matters. You asked about a woman over 50 with hysterectomy on estrogen-only therapy. The closest match is a 2008 randomized trial in postmenopausal women after hysterectomy, which found estrogen therapy did not improve quality of life, while exercise did [10]. That is the only study in this set that matches your population, and it says nothing about duration, overdose, or stopping.
On duration, the evidence is silent. No retrieved study tests how long to take it. On overdose, the closest data is a 2013 trial comparing low-dose (0.3 mg) to standard-dose (0.625 mg) conjugated equine estrogen: both relieved symptoms similarly, but the higher dose improved bone density more, and two women on the higher dose developed simple endometrial hyperplasia [13]. That suggests higher doses carry more risk without more symptom benefit. On stopping, the evidence is also silent. One 2014 perspective notes that in the WHI, stopping estrogen after long deprivation was linked to decreased breast cancer incidence and mortality, but that is about a different population and a different mechanism [5].
The retrieved evidence is mostly off-scope. It includes studies on thyroid medication needs [1], coronary bypass outcomes [2], prostate cancer [9, 24], and adolescent growth [17]. None of these answer your question. The one study that matches your population [10] was small, with 44 women total, and it found no quality-of-life benefit from estrogen. That is a red flag for the intervention's value in this group, but it is not proof of harm either.
| Question | What the evidence shows | Confidence |
|---|---|---|
| How long to take it | No retrieved study tests duration | Not clear |
| Too much estrogen | Higher dose (0.625 mg) gave more bone benefit but caused endometrial hyperplasia in 2/50 women [13] | Low |
| Stopping | No retrieved study on discontinuation in this population | Not clear |
The funding picture is also thin. The 2013 dose trial does not disclose its funder in the record [13]. The 2008 quality-of-life trial does not either [10]. Neither was manufacturer-funded on the face of it, but the absence of disclosure is not the same as independence. The 2000 coronary bypass study was published in Obstetrics & Gynecology and shows a mortality rate of 2.9% for estrogen users versus 7.4% for nonusers, but the confidence interval crosses 1 (0.07 to 1.21), meaning the difference could be chance [2]. That is not evidence of benefit.
What is proven here is narrow. Estrogen relieves hot flushes and sweats in postmenopausal women, with p-values under 0.001 in a 1979 study [3]. It improves bone mineralization, with a 4.42% increase after standard therapy and 6.85% after high doses [4]. It raises thyroid hormone binding globulin, which can increase thyroxine needs in hypothyroid women [1]. None of that tells you how long to take it after hysterectomy.
What is asserted but not proven is the safety of long-term use. No retrieved study follows women for years after hysterectomy on estrogen-only therapy. The 1980 case-control study found long-term conjugated estrogen use raised breast cancer risk in women with intact ovaries (relative risk about 2.5 for high cumulative dose), but found no increased risk in women with prior oophorectomy [23]. That is the closest thing to a long-term safety signal, and it is reassuring for your population, but it is a case-control study from 1980, not a randomized trial.
My call: the evidence does not support a specific duration, does not establish a safe upper dose, and does not tell you what happens on stopping. The burden of proof is on the prescriber to justify continued use, and the one trial in your population found no quality-of-life benefit. Confidence: not clear.
Sources examined 25
-
Increased Need for Thyroxine in Women with Hypothyroidism during Estrogen Therapy
This study investigates the increased need for thyroxine in women with hypothyroidism undergoing estrogen therapy, revealing significant changes in thyroid function and the necessity for dosage adjustments.
DOI: 10.1056/NEJM200106073442302 -
Estrogen therapy in women undergoing coronary artery bypass grafting: effect on surgical complications
This study investigates the impact of estrogen therapy on postoperative complications in postmenopausal women undergoing coronary artery bypass grafting, finding no significant influence on mortality or complications despite some initial univariate benefits.
DOI: 10.1016/s0029-7844(99)00624-9 -
Changes in psychological well-being during postmenopause as a result of estrogen therapy
This study investigates the effects of conjugated estrogen therapy on psychological well-being and climacteric symptoms in postmenopausal women, revealing significant improvements in psychological factors among those receiving long-term treatment.
DOI: 10.1016/0378-5122(79)90021-5 -
Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women
This study investigates the effects of conventional and high doses of estrogen therapy on the degree of mineralization of iliac bone tissue in postmenopausal women, revealing that high-dose therapy significantly increases bone mineralization compared to untreated women.
DOI: 10.1016/j.bone.2004.12.009 -
Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy
This perspective proposes that long-term antihormone therapy (tamoxifen) selects estrogen-deprived cancer cell populations that become vulnerable to estrogen-induced apoptosis, explaining why mortality decreases after stopping tamoxifen and linking clinical trial findings (ATLAS…
DOI: 10.1093/jnci/dju296 -
Impaired very low density lipoprotein and triglyceride removal in broad beta disease: Comparison with endogenous hypertriglyceridemia
This study investigates the impaired removal of very low density lipoprotein (VLDL) and triglycerides in patients with broad beta disease compared to those with endogenous hypertriglyceridemia, revealing significant differences in apoprotein-B turnover rates and the effects of e…
DOI: 10.1016/0026-0495(78)90151-8 -
The effects of hormone therapy, estrogen therapy and tibolone on apoptosis and cyclin D1 expression in postmenopausal vaginal epithelium
This study investigates the effects of hormone therapy, estrogen therapy, and tibolone on apoptosis markers and cyclin D1 expression in postmenopausal vaginal epithelium, finding that only estradiol valerate significantly increased cyclin D1 levels while other treatments did not…
DOI: 10.1016/j.ejogrb.2004.11.029 -
Increased cardiovascular response to caffeine in perimenopausal women before and during estrogen therapy
This study investigates the cardiovascular and catecholamine response to caffeine in perimenopausal women compared to premenopausal women, revealing that perimenopausal women exhibit a heightened cardiovascular reactivity to caffeine both before and during estrogen therapy.
DOI: 10.1530/eje.0.1350598 -
Prostate carcinoma-therapeutic considerations in the management of gross lymph node metastases
This study investigates the efficacy of combining estrogen therapy with megavoltage radiotherapy in treating prostate carcinoma patients with gross lymph node metastases, reporting a 68% disease-free survival rate among the treated cohort.
DOI: 10.1016/0360-3016(79)90074-9 -
A randomized, placebo-controlled trial of the effects of physical exercises and estrogen therapy on health-related quality of life in postmenopausal women
This study evaluates the isolated and combined effects of estrogen therapy and physical exercise on health-related quality of life and menopausal symptoms in postmenopausal women who have undergone hysterectomy, finding that physical exercise significantly improves quality of li…
DOI: 10.1097/gme.0b013e3181605494 -
Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study
This pilot study investigates the effects of transdermal estrogen therapy on skin water-holding capacity in menopausal women, revealing significant improvements in skin capacitance at the site of occlusion stress test compared to untreated controls.
DOI: 10.1016/0378-5122(95)00924-a -
PWH5 QUALITY OF LIFE (QOL) DIFFERENTIATION ANALYSIS IN PATIENTS UNDERGOING CONTROLLED OVARIAN STIMULATION (COS) WITH TWO DIFFERENT PREPARATIONS OF RECOMBINANT HUMAN FOLLICLESTIMULATING HORMONE (R-HFSH)
This study evaluates the impact of pulsed estrogen therapy using intranasal 17-beta estradiol on the quality of life of women in the early postmenopausal period, demonstrating significant improvements in various quality of life metrics after treatment.
DOI: 10.1016/s1098-3015(10)61805-0 -
Comparative Study of Low Dose Conjugate Equine Estrogen 0.3 mg vs Standard Dose Conjugate Equine Estrogen 0.625 mg as Hormone Replacement Therapy
A randomized 1-year clinical trial in 100 postmenopausal women comparing low-dose (0.3 mg) versus standard-dose (0.625 mg) conjugated equine estrogen for hormone replacement therapy; both doses provided similar relief of vasomotor/genitourinary/psychological symptoms, but the hi…
DOI: 10.5005/jp-journals-10032-1011 -
Aspirin and Serum Estrogens in Postmenopausal Women: A Randomized Controlled Clinical Trial
Six months of daily aspirin for 325 mg did not change serum estrogens (estrone, estradiol, free estradiol, bioavailable estradiol) or SHBG in 144 healthy postmenopausal women.
DOI: 10.1158/1940-6207.capr-14-0109 -
Influence of High-Dose Estrogen Exposure during Adolescence on Mammographic Density for Age in Adulthood
This study investigates the long-term effects of high-dose estrogen exposure during adolescence on mammographic density in adulthood, finding that treated women had significantly lower dense area compared to untreated women, suggesting a reduced risk of breast cancer through thi…
DOI: 10.1158/1055-9965.epi-09-0434 -
Radiotherapy at a young age reduces uterine volume of childhood cancer survivors
This study investigates the impact of radiotherapy on uterine volume in childhood cancer survivors, revealing that direct uterine irradiation significantly reduces uterine size and that high-dose estrogen replacement therapy does not improve uterine volume in patients with ovari…
DOI: 10.1080/j.1600-0412.2004.00332.x -
Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature
This study investigates the differential effects of high-dose estrogen and testosterone treatments on circulating insulin-like growth factor (IGF) system components in adolescents with constitutional tall stature, revealing significant changes in IGF-I, IGF-II, and IGFBPs in res…
DOI: 10.1530/eje.1.01880 -
Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors
This study demonstrates that high doses of 17β-estradiol stimulate the growth of breast tumor cells independently of estrogen receptor status, while tamoxifen inhibits growth similarly in both receptor-positive and receptor-negative cell lines.
DOI: 10.1007/bf01806774 -
Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients
This study evaluates the long-term outcomes of high-dose selective estrogen receptor modulators and sulindac in treating sporadic and familial adenomatous polyposis (FAP)-associated desmoid tumors in 134 patients, finding an overall response rate of 85.1%.
DOI: 10.1007/s10689-015-9830-z -
Oral Contraceptives and Stroke
A comprehensive epidemiological review of how oral contraceptives influence stroke risk, showing increased risk with current use—especially high-estrogen formulations—modulated by hypertension, smoking, migraine, and cerebral venous thrombosis, with substantial regional variatio…
DOI: 10.1046/j.1468-2982.2000.00040.x -
Nitric-Oxide-Dependent Pial Arteriolar Dilation in the Female Rat: Effects of Chronic Estrogen Depletion and Repletion
This study investigates the effects of chronic estrogen depletion and repletion on endothelial nitric oxide synthase (eNOS)-mediated cerebral vasodilation in female rats, revealing that estrogen significantly influences eNOS expression and vascular reactivity.
DOI: 10.1006/bbrc.2000.2206 -
Selective Estrogen Receptor Modulator and prostimulatory effects of phytoestrogen β-ecdysone in Tinospora cordifolia on osteoblast cells
This study investigates the potential of Tinospora cordifolia as a Selective Estrogen Receptor Modulator (SERM) and the osteoprotective effects of its active compound, b-ecdysone, on osteoblast cells, revealing both therapeutic benefits and potential toxic effects at high doses.
DOI: 10.1016/j.jaim.2017.04.003 -
A Case-Control Study of Menopausal Estrogen Therapy and Breast Cancer
A population-based case-control study in two Los Angeles retirement communities found that long-term use of conjugated estrogen therapy increases breast cancer risk in women with intact ovaries (RR ~2.5 for accumulated dose ≥1,500 mg), while no increased risk was observed in wom…
DOI: 10.1001/JAMA.1980.03300420019018 -
Transdermal estrogen in the treatment of hot flushes in men with prostate cancer
This small randomized crossover trial evaluated the efficacy and tolerability of low-dose (0.05 mg) versus high-dose (0.10 mg) transdermal estrogen patches for hot flashes in men undergoing androgen deprivation therapy for prostate cancer, finding that both doses reduced severit…
DOI: 10.1016/s0090-4295(99)00370-2 -
Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women.
In a small prospective study of premenopausal women, very high-dose oral medroxyprogesterone acetate (50 mg/day) caused rapid, largely reversible loss of lumbar spine bone mineral density—likely via estrogen deficiency—with no significant change at the femoral neck over 6–12 mon…
DOI: 10.1210/jcem.81.3.8772567